Status:
RECRUITING
Safety and Efficacy of Lactobacillus Plantarum for Psoriasis: A Randomized Double-Blind Placebo-Controlled Trial
Lead Sponsor:
Shenzhen People's Hospital
Conditions:
Psoriasis
Lactobacillus Plantarum
Eligibility:
All Genders
16-60 years
Phase:
PHASE2
Brief Summary
A growing body of evidence indicates that the pathogenesis of psoriasis may be closely linked to skin microbiome dysbiosis. Compared with healthy individuals, the composition and function of the skin ...
Eligibility Criteria
Inclusion
- Reference to Psoriasis Area and Severity Index (PASI) score \< 10 Patients have been informed of the study details, voluntarily participate, and have signed the informed consent form; Aged 18-60 years with good general health status; No use of any medications within 6 months; No various inflammatory or immune skin diseases, no local infections, and no neuromuscular diseases.
Exclusion
- Patients with other types of psoriasis or severe psoriasis; Those in the active phase of skin diseases or with other serious diseases; Other situations deemed unsuitable for enrollment by the researchers, such as subjects who are untrustworthy, unable to accept or understand the study assessments.
Key Trial Info
Start Date :
December 15 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2026
Estimated Enrollment :
184 Patients enrolled
Trial Details
Trial ID
NCT07194200
Start Date
December 15 2025
End Date
June 30 2026
Last Update
December 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shenzhen People's Hospital
Shenzhen, Guangdong, China